VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (VYNE)
CUSIP: 92941V308
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock, par value $0.0001
- Shares outstanding
- 33,333,333
- Total 13F shares
- 7,942,286
- Share change
- +142,864
- Total reported value
- $16,030,293
- Price per share
- $1.97
- Number of holders
- 30
- Value change
- +$243,077
- Number of buys
- 14
- Number of sells
- 11
Quarterly Holders Quick Answers
What is CUSIP 92941V308?
CUSIP 92941V308 identifies VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92941V308:
Top shareholders of VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,935,057
|
$11,251,930 | — | 16 Aug 2021 | |
| Cormorant Asset Management, LP |
13F
|
Company |
4.2%
|
1,394,336
|
$4,280,612 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
3.5%
|
1,181,088
|
$3,625,940 | — | 31 Mar 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
4.2%
|
1,394,336
|
$3,130,284 | — | 31 Mar 2024 | |
| AI Biotechnology LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,116,585
|
$2,545,814 | — | 01 Nov 2023 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
2.1%
|
696,470
|
$2,138,163 | — | 31 Mar 2024 | |
| DSC Advisors, L.P. |
13F
|
Company |
2.1%
|
696,465
|
$2,138,148 | — | 31 Mar 2024 | |
| Palo Alto Investors LP |
13F
|
Company |
1.3%
|
445,434
|
$1,367,482 | — | 31 Mar 2024 | |
| AlphaCentric Advisors LLC |
13F
|
Company |
1.3%
|
445,000
|
$1,366,150 | — | 31 Mar 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
1.2%
|
415,434
|
$1,275,382 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.66%
|
219,800
|
$674,786 | — | 31 Mar 2024 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.53%
|
175,372
|
$538,000 | — | 31 Mar 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.33%
|
110,091
|
$337,979 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.32%
|
106,775
|
$327,823 | — | 31 Mar 2024 | |
| PRELUDE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.28%
|
94,600
|
$290,422 | — | 31 Mar 2024 | |
| Andrew Saik |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
116,468
|
$265,547 | — | 28 May 2021 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.26%
|
86,383
|
$265,196 | — | 31 Mar 2024 | |
| Matthew T. Wiley |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
109,246
|
$249,081 | — | 30 Jun 2021 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.24%
|
80,576
|
$247,000 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.21%
|
69,633
|
$213,773 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.18%
|
60,323
|
$185,192 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.13%
|
44,618
|
$136,977 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.11%
|
36,951
|
$113,440 | — | 31 Mar 2024 | |
| STALEY CAPITAL ADVISERS INC |
13F
|
Company |
—
class O/S missing
|
36,472
|
$111,969 | — | 31 Mar 2024 | |
| Virtu Financial LLC |
13F
|
Company |
0.05%
|
16,199
|
$50,000 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.03%
|
11,665
|
$35,812 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.03%
|
10,990
|
$33,739 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
2,187
|
$6,714 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
1,868
|
$5,735 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,241
|
$3,810 | — | 31 Mar 2024 | |
| MB, LEVIS & ASSOCIATES, LLC |
13F
|
Company |
0%
|
1,041
|
$3,196 | — | 31 Mar 2024 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0%
|
187
|
$574 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
174
|
$535 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
169
|
$520 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
16
|
$49 | — | 31 Mar 2024 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
—
class O/S missing
|
2
|
$6 | — | 31 Mar 2024 | |
| Rex Bright |
3/4/5
|
Director |
—
class O/S missing
|
20,500
|
— | — | 19 Jul 2021 |
Institutional Holders of VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (VYNE) as of Q2 2024
As of 30 Jun 2024,
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 (VYNE) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,942,286 shares.
The largest 10 holders included
EVENTIDE ASSET MANAGEMENT, LLC, Cormorant Asset Management, LP, CITADEL ADVISORS LLC, DSC Advisors, L.P., SILVERARC CAPITAL MANAGEMENT, LLC, Palo Alto Investors LP, VANGUARD GROUP INC, Exome Asset Management LLC, Parkman Healthcare Partners LLC, and AlphaCentric Advisors LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
29
Q2 2024 holders
30
Holder diff
1
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.